{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016344","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.063656+00:00","generated_at":"2026-05-29T02:00:44.561182+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MetaVia (MTVA) announces positive Phase 2a top-line results for DA-1241 in MASH patients","bullets":["DA-1241 100mg achieved statistically significant ALT reduction at weeks 4 and 8 (p=0.0159, p=0.0342), near significant at week 16 (p=0.0506).","Statistically significant improvements in CAP score (p=0.0308) and HbA1C (p=0.0179) vs placebo at week 16.","DA-1241 was very well tolerated; no drug-related serious adverse events reported across treatment groups.","Company plans end-of-Phase 2 meeting with FDA in first half of 2025; full data set awaited.","DA-1241 100mg + sitagliptin also showed significant FAST score reduction (p=0.0416)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016344","json":"https://secwatch.observer/filing/0001558370-24-016344.json","markdown":"https://secwatch.observer/filing/0001558370-24-016344.md","text":"https://secwatch.observer/filing/0001558370-24-016344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024016344/0001558370-24-016344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024016344/mtva-20241218x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:00:44.561182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}